Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7

1.

Efficacy and Acceptability of Glycemic Control of Glucagon-Like Peptide-1 Receptor Agonists among Type 2 Diabetes: A Systematic Review and Network Meta-Analysis.

Li Z, Zhang Y, Quan X, Yang Z, Zeng X, Ji L, Sun F, Zhan S.

PLoS One. 2016 May 9;11(5):e0154206. doi: 10.1371/journal.pone.0154206. eCollection 2016. Review.

2.

Glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes: Past, present, and future.

Kalra S, Baruah MP, Sahay RK, Unnikrishnan AG, Uppal S, Adetunji O.

Indian J Endocrinol Metab. 2016 Mar-Apr;20(2):254-67. doi: 10.4103/2230-8210.176351. Review.

3.

Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists.

Madsbad S.

Diabetes Obes Metab. 2016 Apr;18(4):317-32. doi: 10.1111/dom.12596. Epub 2015 Dec 29. Review.

4.

Gastrointestinal adverse events of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a systematic review and network meta-analysis.

Sun F, Chai S, Yu K, Quan X, Yang Z, Wu S, Zhang Y, Ji L, Wang J, Shi L.

Diabetes Technol Ther. 2015 Jan;17(1):35-42. doi: 10.1089/dia.2014.0188. Review.

5.

Molecular mechanisms underlying physiological and receptor pleiotropic effects mediated by GLP-1R activation.

Pabreja K, Mohd MA, Koole C, Wootten D, Furness SG.

Br J Pharmacol. 2014 Mar;171(5):1114-28. doi: 10.1111/bph.12313. Review.

6.

Recent progress and future options in the development of GLP-1 receptor agonists for the treatment of diabesity.

Lorenz M, Evers A, Wagner M.

Bioorg Med Chem Lett. 2013 Jul 15;23(14):4011-8. doi: 10.1016/j.bmcl.2013.05.022. Epub 2013 May 16. Review.

7.

GLP-1 receptor agonists or DPP-4 inhibitors: how to guide the clinician?

Scheen AJ.

Ann Endocrinol (Paris). 2013 Dec;74(5-6):515-22. doi: 10.1016/j.ando.2012.06.002. Epub 2013 Apr 6. Review.

Supplemental Content

Loading ...
Support Center